Logo
  • About
    • What We Do
    • Team
    • Partners
  • Pipeline
  • Technologies
    • FastPharming®
    • Glycaneering℠
    • LicKM
    • VLP
  • Products
  • Resources
    • News
    • Events
    • Media
    • Scientific Content
  • Careers
  • Investors
  • Contact
  • Therapeutics
    • Oncology
      • IBIO-101
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-202
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Bioanalytics
    • mAb Solutions
    • Aseptic Fill/Finish
    • Factory Solutions
Investors

Press Releases

Investors

Investors

  • Overview
  • Company Info
    • Profile
    • Management Team
    • Presentations
  • News & Events
    • Press Releases
    • IR Calendar
  • Stock Data
    • Quote
    • Historical Data
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
    • IR Contact
    • Email Alerts
    • Investor FAQ
  • News & Events

  • Press Releases
  • IR Calendar
May 18, 2022 8:00am EDT

iBio to Participate in the H.C. Wainwright Global Investment Conference

May 12, 2022 4:05pm EDT

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

May 09, 2022 8:00am EDT

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

May 05, 2022 4:30pm EDT

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

May 02, 2022 8:00am EDT

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Mar 11, 2022 8:00am EST

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

Feb 14, 2022 4:05pm EST

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

Feb 07, 2022 4:30pm EST

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

Jan 26, 2022 9:00am EST

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

Jan 04, 2022 4:30pm EST

iBio Announces Participation in the H.C. Wainwright BioConnect Conference

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …15
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Footer Logo
  • Therapeutics
    • Oncology
      • IBIO-101
    • Fibrosis
      • IBIO-100
  • Vaccines
    • Covid-19
      • IBIO-202
    • Classic Swine Fever
      • IBIO-400
  • Research & Bioprocess
  • CDMO Services
    • Process Development
    • cGMP Manufacturing
    • Aseptic Fill/Finish
    • Bioanalytics
    • mAb Solutions
    • Factory Solutions

iBio, Inc.
iBio CDMO, LLC

8800 HSC Pkwy
Bryan, TX 77807

(979) 446-0027
LinkedIn
info@ibioinc.com
RSS News Feed

© 2022 iBio. All Rights Reserved.
Privacy Policy
Terms and Conditions

  • About
  • Pipeline
  • Technologies
  • Products
  • Resources
  • Careers
  • Investors
  • Contact